The lack of immunogenicity has practical implications: the peptide can be used for extended periods without loss of efficacy due to antibody neutralization, there is minimal risk of allergic or hypersensitivity reactions, and repeated treatment cycles are supported as prior exposure does not sensitize the immune system
GLP-1RA use was associated with 3.0 additional ION cases per 10,000 vs SGLT2i (NNH: 3,333) and 3.6 vs DPP-4i (NNH 2,778)
Ranson H et al
Andy Hsieh, a biotech analyst at the investment bank William Blair, says his initial reaction upon seeing Novo Nordisks findings was, Oh man
Benefits: Skin whitening, glow enhancement, detoxification, and hydration
Global, regional, and national sepsis incidence and mortality, 19902017: analysis for the global burden of disease study